AT PATIENT TESTING® IS NOW A REALITY

At Patient Testing® represents a deployable and scalable strategy, for delivering actionable results, in under 30 minutes, at the Point-of-Decision, and so helping to improve global health outcomes – but most importantly save lives.

Lab-grade sensitivity and specificity molecular diagnostics, performed directly from crude samples including saliva, swabs and including whole, unprocessed blood — without extraction, lab infrastructure, or specialist personnel.

Designed for both humans and animals, and deployable in labs or in-field. Point-of-Decision results without delay, enables early detection, triage, intervention and outbreak control.

One Health capability — all at minimal operational and economic cost.

Containment must begin where the first outbreak starts.

Pandemics often emerge at the intersection of human, animal, and environmental health. Delays in early detection increase the risk of uncontrolled spread and outbreaks, particularly in zoonotic, veterinary or vector-borne events. Proactive and targeted surveillance is integral to ensuring the early detection of emerging infectious diseases.

At Patient Testing® (APT®) enables rapid, decentralised molecular surveillance directly at the focal point of infection—in-field, farm-side, or frontline care. With CENOS™, testing doesn't wait for the sample to reach the lab. Instead, high-sensitivity real-time detection can be performed on-site in under 30 minutes, by trained users with no specialist molecular expertise required.

CENOS™ is GPS-enabled, allowing real-time mapping of transmission and identification of emerging clusters. This supports data-driven triage, rapid isolation, and faster deployment of effective containment strategies to contain outbreaks.

Most critically, in the face of the inevitable threat of Disease X, CENOS™ offers unmatched responsiveness. Backed by an ISO 13485 certified quality system, our development team can go from target alignment data to a validated frontline assay in just 4–6 weeks — a pace that outperforms conventional lab-based systems and commercial molecular development pipelines.

Our in-house assay design capabilities and the inherent simplicity of the CENOS™ platform allow for rapid scale-up of both reagents and instruments—ensuring we’re ready to respond at speed and scale.

CENOS™ complements existing labs, vaccination programs, and lateral flow tools — but it fills the vital gap at the Point-of-Decision, delivering rapid, lab-grade molecular results exactly where and when they’re needed to contain transmission early.

Disease doesn’t respect species, borders, or supply chains. Whether in rural farms, wildlife zones, local clinics, or major transport hubs, early detection without delay at the source is paramount to stopping outbreaks before they escalate into public health emergencies and devastate people’s lives.

APT® using CENOS™ enables front-line containment, faster evidence based decision-making, and real-time tracking of disease threats across both veterinary and human health sectors. This directly supports the One Health model ensuring health systems, food chains, ecosystems are protected, unified and resilient.

The CENOS™ platform supports localised molecular testing in primary care settings such as community clinics, GP surgeries, pharmacies and mobile testing units. This strengthens response and improves equity in underserved or remote communities. People are more proactive and receptive to testing efforts if they can be readily accessed locally in their community instead of having to travel to centralised testing facilities.

Our platform technology is simple, low cost and easy to use with minimal requirements for specialist personnel, facilities, equipment or sample processing. This means gold-standard molecular diagnostics can be easily accessed by those who need it most - helping to improve global health outcomes and ultimately save lives.

Test to result in under 30 minutes, no need for extraction, cold-chain free reagents and can be powered using off-grid power sources including battery, vehicle or solar. CENOS™ provides high-sensitivity real-time PCR capability anywhere whilst the subject waits — from rural farms to community clinics.

CENOS™ enables hospitals and labs to expand molecular testing capacity without infrastructure overhaul. In critical or deteriorating cases typically seen in ambulances, A&E, ICUs, resuscitation rooms and high acuity units, there is no time to wait for lab-based testing with long turnaround times. CENOS™ delivers real-time PCR results in under 30 minutes improving triage, reduce turnaround, and accelerating time-critical decision-making—directly improving patient outcomes.

The platform focuses on achieving better health outcomes for patients, service users and the wider population, improving the experience of both patients and staff, and ensuring the most efficient use of resources. CENOS™ delivers high-quality diagnostics that are simple, effective, timely, efficient, and patient-centred, with a focus on prevention, innovation, and continuous improvement.

APT® using CENOS™ has advantages for specimen stability and ease of handling. There is reduced risk of sample deterioration and contamination as the test is performed rapidly after the sample has been collected. No need for samples to be transported to central laboratory facilities or stored in specialist conditions. This significantly reduces downstream costs, turnaround times, plasticware and paperwork required streamlining the workflow process. 

No need to send samples to central reference laboratories. The CENOS™ platform can perform preliminary testing to rapidly identify and contain notifiable diseases such as Foot and Mouth Disease (FMD), African Swine Fever Virus (ASFV), Avian influenza Virus (AIV), Foot and Mouth Disease FMDV). These Transboundary Animal Diseases cause significant economic losses due to livestock being killed or culled, disease control measures and export restrictions.

Sample to result time in under 30 minutes means infected livestock can be rapidly identified and quarantined without delay helping to minimise losses to livestock and farmers. CENOS™ protects livestock health and welfare, agricultural trade, supply chains and farmers' livelihoods.

Low cost per test using CENOS™ means it is accessible, commercially feasible and beneficial for farmers to test their livestock instead of culling them as a preventive measure. CENOS™ can be used by non-veterinarians with minimal training and no molecular expertise. There is no nucleic extraction processes or complex workflows.

Surveillance efforts using CENOS™ can be targeted precisely where they are required for the identification and reporting of diseases. Animal health surveillance is crucial in determining the absence, presence and distribution of animal diseases and detecting emerging or re-emerging diseases as early as possible. Data generated by CENOS™ can be used to assess the risk and impact of infectious diseases to both animal and public health. The necessary actions and control measures can then be implemented to prevent onward transmission. CENOS™ supports targeted animal health surveillance in livestock and wildlife.

  • Influenza A / B
  • SARS-CoV-2
  • RSV
  • Emerging respiratory threats
  • Influenza A / B
  • SARS-CoV-2
  • RSV
  • Emerging respiratory threats
  • Filoviruses (Ebola, Marburg)
  • Arenaviruses (Lassa)
  • Emerging high-consequence haemorrhagic agents
  • Norovirus
  • Rotavirus
  • Enteric adenoviruses
  • Emerging gastrointestinal threats

CENOS™ supports real-time surveillance of zoonotic threats across species including reservoirs and disease vectors. A portable real-time PCR platform technology that can be deployed anywhere in the world to monitor and gather surveillance data. CENOS™ enables frontline teams to detect, contain, and intercept the transmission of zoonotic diseases directly at their point of origin - before they establish themselves and spillover into human populations.

CENOS™ delivers ruggedised, in-theatre diagnostics for military personnel health protection and bio-threat response. Lightweight, simple to use, battery-compatible, and fast—our platform supports operational readiness, outbreak containment, and biological defence across hostile and remote environments where troops are forwardly deployed.

The first line of defence for countries or regions against infectious diseases from external origins. CENOS™ can be deployed to border control checkpoints, airports or seaports for rapid screening of infectious diseases. Sample to result in under 30 minutes, subjects can be held in quarantine until they have been tested. Data from testing also supports surveillance activities tracking the spread and progression of infectious diseases around the world. A robust molecular screening infrastructure at ports of entry and borders is integral to preventing the global spread of infectious diseases.

APT® using CENOS™ provides screening capacity at major events with high-footfall – such as religious, music and sporting events. Attendees can be screened in under 30 minutes prior to entry ensuring there is no onwards transmission of infectious diseases to others. The continuation of major events is important to preserve historical legacies, religious practises, social and economic benefits. CENOS™ helps ensure the safety of attendees of major events through effective and accessible screening.